US6673335B1
(en)
*
|
1992-07-08 |
2004-01-06 |
Nektar Therapeutics |
Compositions and methods for the pulmonary delivery of aerosolized medicaments
|
EP0679088B1
(en)
*
|
1992-09-29 |
2002-07-10 |
Inhale Therapeutic Systems |
Pulmonary delivery of active fragments of parathyroid hormone
|
US7448375B2
(en)
*
|
1993-01-29 |
2008-11-11 |
Aradigm Corporation |
Method of treating diabetes mellitus in a patient
|
US6024090A
(en)
*
|
1993-01-29 |
2000-02-15 |
Aradigm Corporation |
Method of treating a diabetic patient by aerosolized administration of insulin lispro
|
US5830853A
(en)
|
1994-06-23 |
1998-11-03 |
Astra Aktiebolag |
Systemic administration of a therapeutic preparation
|
US6632456B1
(en)
|
1993-06-24 |
2003-10-14 |
Astrazeneca Ab |
Compositions for inhalation
|
US6794357B1
(en)
|
1993-06-24 |
2004-09-21 |
Astrazeneca Ab |
Compositions for inhalation
|
US20010003739A1
(en)
*
|
1993-06-24 |
2001-06-14 |
Astrazeneca Ab |
Systemic administration of a therapeutic preparation
|
TW402506B
(en)
|
1993-06-24 |
2000-08-21 |
Astra Ab |
Therapeutic preparation for inhalation
|
US6051256A
(en)
*
|
1994-03-07 |
2000-04-18 |
Inhale Therapeutic Systems |
Dispersible macromolecule compositions and methods for their preparation and use
|
DK0748213T3
(da)
|
1994-03-07 |
2004-08-02 |
Nektar Therapeutics |
Fremgangsmåder og sammensætninger til pulmonal indgivelse af insulin
|
CA2190502A1
(en)
*
|
1994-05-18 |
1995-11-23 |
Robert M. Platz |
Methods and compositions for the dry powder formulation of interferons
|
US6165976A
(en)
|
1994-06-23 |
2000-12-26 |
Astra Aktiebolag |
Therapeutic preparation for inhalation
|
US6290991B1
(en)
*
|
1994-12-02 |
2001-09-18 |
Quandrant Holdings Cambridge Limited |
Solid dose delivery vehicle and methods of making same
|
US6524557B1
(en)
|
1994-12-22 |
2003-02-25 |
Astrazeneca Ab |
Aerosol formulations of peptides and proteins
|
ES2197212T3
(es)
*
|
1994-12-22 |
2004-01-01 |
Astrazeneca Ab |
Preparacion terapeutica para inhalacion que contiene la hormona paratiroidea, pth.
|
EE9700138A
(et)
|
1994-12-22 |
1997-12-15 |
Astra Aktiebolag |
Aerosoolravimvormid
|
US6258341B1
(en)
|
1995-04-14 |
2001-07-10 |
Inhale Therapeutic Systems, Inc. |
Stable glassy state powder formulations
|
US6019968A
(en)
*
|
1995-04-14 |
2000-02-01 |
Inhale Therapeutic Systems, Inc. |
Dispersible antibody compositions and methods for their preparation and use
|
US6165463A
(en)
*
|
1997-10-16 |
2000-12-26 |
Inhale Therapeutic Systems, Inc. |
Dispersible antibody compositions and methods for their preparation and use
|
US6309671B1
(en)
|
1995-04-14 |
2001-10-30 |
Inhale Therapeutic Systems |
Stable glassy state powder formulations
|
US6428771B1
(en)
*
|
1995-05-15 |
2002-08-06 |
Pharmaceutical Discovery Corporation |
Method for drug delivery to the pulmonary system
|
GB9515182D0
(en)
*
|
1995-07-24 |
1995-09-20 |
Co Ordinated Drug Dev |
Improvements in and relating to powders for use in dry powder inhalers
|
DK0877602T3
(da)
|
1996-01-24 |
2002-05-06 |
Byk Gulden Lomberg Chem Fab |
Fremgangsmåde til fremstilling af pulverformede lungesurfactant-præparater
|
US6254854B1
(en)
|
1996-05-24 |
2001-07-03 |
The Penn Research Foundation |
Porous particles for deep lung delivery
|
US6503480B1
(en)
*
|
1997-05-23 |
2003-01-07 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US20030203036A1
(en)
*
|
2000-03-17 |
2003-10-30 |
Gordon Marc S. |
Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
|
US20030035778A1
(en)
*
|
1997-07-14 |
2003-02-20 |
Robert Platz |
Methods and compositions for the dry powder formulation of interferon
|
IL134084A0
(en)
|
1997-07-18 |
2001-04-30 |
Infimed Inc |
Biodegradable macromers for the controlled release of biologically active substances
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
US6309623B1
(en)
*
|
1997-09-29 |
2001-10-30 |
Inhale Therapeutic Systems, Inc. |
Stabilized preparations for use in metered dose inhalers
|
US6565885B1
(en)
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
US6541606B2
(en)
|
1997-12-31 |
2003-04-01 |
Altus Biologics Inc. |
Stabilized protein crystals formulations containing them and methods of making them
|
TW581681B
(en)
|
1998-02-20 |
2004-04-01 |
Nektar Therapeutics |
Liquid crystal forms of cyclosporin
|
EP2311436A1
(en)
|
1998-04-27 |
2011-04-20 |
Altus Pharmaceuticals Inc. |
Stabilized protein crystals, formulations containing them and methods of making them
|
WO1999055362A1
(en)
*
|
1998-04-29 |
1999-11-04 |
Genentech, Inc. |
Spray dried formulations of igf-i
|
US6284282B1
(en)
|
1998-04-29 |
2001-09-04 |
Genentech, Inc. |
Method of spray freeze drying proteins for pharmaceutical administration
|
GB9810559D0
(en)
*
|
1998-05-15 |
1998-07-15 |
Bradford Particle Design Ltd |
Method and apparatus for particle formation
|
US6451349B1
(en)
|
1998-08-19 |
2002-09-17 |
Quadrant Healthcare (Uk) Limited |
Spray-drying process for the preparation of microparticles
|
US6956021B1
(en)
|
1998-08-25 |
2005-10-18 |
Advanced Inhalation Research, Inc. |
Stable spray-dried protein formulations
|
US20070212422A1
(en)
*
|
1999-11-10 |
2007-09-13 |
Manfred Keller |
Dry powder for inhalation
|
DK1165050T3
(da)
|
1999-04-05 |
2006-05-01 |
Mannkind Corp |
Fremgangsmåde til dannelse af fint pulver
|
EP1169053A1
(en)
|
1999-04-13 |
2002-01-09 |
Inhale Therapeutic Systems, Inc. |
Pulmonary administration of dry powder formulations for treating infertility
|
WO2000061178A1
(en)
*
|
1999-04-13 |
2000-10-19 |
Inhale Therapeutics Systems, Inc. |
Pulmonary administration of dry powder formulations for treating infertility
|
JP4874483B2
(ja)
|
1999-06-09 |
2012-02-15 |
ロバート イー. シーバース |
超臨界流体補助ネブライゼーション及びバブル乾燥
|
US6858199B1
(en)
|
2000-06-09 |
2005-02-22 |
Advanced Inhalation Research, Inc. |
High efficient delivery of a large therapeutic mass aerosol
|
WO2001000654A2
(en)
*
|
1999-06-29 |
2001-01-04 |
Pharmaceutical Discovery Corporation |
Purification and stabilization of peptide and proteins in pharmaceutical agents
|
US9006175B2
(en)
|
1999-06-29 |
2015-04-14 |
Mannkind Corporation |
Potentiation of glucose elimination
|
AU780327B2
(en)
*
|
1999-06-30 |
2005-03-17 |
Novartis Ag |
Spray drying process for preparing dry powders
|
EP1074248A1
(en)
*
|
1999-07-08 |
2001-02-07 |
Arnold Hilgers |
Delivery system for biological material
|
ITMI991582A1
(it)
*
|
1999-07-16 |
2001-01-16 |
Chiesi Farma Spa |
Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
|
US6749835B1
(en)
|
1999-08-25 |
2004-06-15 |
Advanced Inhalation Research, Inc. |
Formulation for spray-drying large porous particles
|
US7678364B2
(en)
|
1999-08-25 |
2010-03-16 |
Alkermes, Inc. |
Particles for inhalation having sustained release properties
|
US6586008B1
(en)
*
|
1999-08-25 |
2003-07-01 |
Advanced Inhalation Research, Inc. |
Use of simple amino acids to form porous particles during spray drying
|
US20010036481A1
(en)
*
|
1999-08-25 |
2001-11-01 |
Advanced Inhalation Research, Inc. |
Modulation of release from dry powder formulations
|
AU763041B2
(en)
*
|
1999-08-25 |
2003-07-10 |
Alkermes, Inc. |
Modulation of release from dry powder formulations
|
US7252840B1
(en)
|
1999-08-25 |
2007-08-07 |
Advanced Inhalation Research, Inc. |
Use of simple amino acids to form porous particles
|
HU229310B1
(en)
|
1999-10-29 |
2013-10-28 |
Nektar Therapeutics |
Dry powder compositions having improved dispersivity
|
US7507687B2
(en)
*
|
2000-03-22 |
2009-03-24 |
Cabot Corporation |
Electrocatalyst powders, methods for producing powder and devices fabricated from same
|
WO2001085136A2
(en)
*
|
2000-05-10 |
2001-11-15 |
Alliance Pharmaceutical Corporation |
Phospholipid-based powders for drug delivery
|
US8404217B2
(en)
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
US20030003057A1
(en)
*
|
2000-07-07 |
2003-01-02 |
Jeffry Weers |
Methods for administering leuprolide by inhalation
|
US7575761B2
(en)
*
|
2000-06-30 |
2009-08-18 |
Novartis Pharma Ag |
Spray drying process control of drying kinetics
|
WO2002009669A2
(en)
*
|
2000-08-01 |
2002-02-07 |
Inhale Therapeutic Systems, Inc. |
Apparatus and process to produce particles having a narrow size distribution and particles made thereby
|
JP2004515467A
(ja)
|
2000-08-07 |
2004-05-27 |
ネクター セラピューティックス |
吸入可能な、噴霧乾燥した、最少の凝集物を有する4−ヘリックスバンドルタンパク質粉末
|
JP2004523479A
(ja)
*
|
2000-10-18 |
2004-08-05 |
マサチューセッツ インスティテュート オブ テクノロジー |
多糖の肺送達に関する方法および産物
|
US7374782B2
(en)
|
2000-10-27 |
2008-05-20 |
Baxter International Inc. |
Production of microspheres
|
GB0027357D0
(en)
|
2000-11-09 |
2000-12-27 |
Bradford Particle Design Plc |
Particle formation methods and their products
|
EP1351704B1
(en)
*
|
2000-12-21 |
2007-03-07 |
Nektar Therapeutics |
Storage stable powder compositions of interleukin-4 receptor
|
US20020141946A1
(en)
*
|
2000-12-29 |
2002-10-03 |
Advanced Inhalation Research, Inc. |
Particles for inhalation having rapid release properties
|
US6887462B2
(en)
|
2001-04-09 |
2005-05-03 |
Chiron Corporation |
HSA-free formulations of interferon-beta
|
US6848197B2
(en)
*
|
2001-04-18 |
2005-02-01 |
Advanced Inhalation Research, Inc. |
Control of process humidity to produce large, porous particles
|
US20070042983A1
(en)
*
|
2001-05-18 |
2007-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050287128A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
|
US20050267058A1
(en)
*
|
2001-05-18 |
2005-12-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
|
US20050143333A1
(en)
*
|
2001-05-18 |
2005-06-30 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050159380A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
|
US20050227935A1
(en)
*
|
2001-05-18 |
2005-10-13 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
|
US20050164968A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
|
US7517864B2
(en)
*
|
2001-05-18 |
2009-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20060241075A1
(en)
*
|
2001-05-18 |
2006-10-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
|
US20050014172A1
(en)
*
|
2002-02-20 |
2005-01-20 |
Ivan Richards |
RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
|
US20050233997A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US20050282188A1
(en)
*
|
2001-05-18 |
2005-12-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20070270579A1
(en)
*
|
2001-05-18 |
2007-11-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050119212A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
|
US20050233344A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
|
US20050159382A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US20050176664A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
|
US20080161256A1
(en)
*
|
2001-05-18 |
2008-07-03 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050187174A1
(en)
*
|
2001-05-18 |
2005-08-25 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
|
US20050203040A1
(en)
*
|
2001-05-18 |
2005-09-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
US20050176666A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
|
US20050288242A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
|
US20050159376A1
(en)
*
|
2002-02-20 |
2005-07-21 |
Slrna Therapeutics, Inc. |
RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
|
US20050222066A1
(en)
*
|
2001-05-18 |
2005-10-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050182007A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050054596A1
(en)
*
|
2001-11-30 |
2005-03-10 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050182009A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
|
US20050148530A1
(en)
*
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20060019913A1
(en)
*
|
2001-05-18 |
2006-01-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US20050256068A1
(en)
*
|
2001-05-18 |
2005-11-17 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
|
US20040198682A1
(en)
*
|
2001-11-30 |
2004-10-07 |
Mcswiggen James |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
|
NZ519403A
(en)
*
|
2001-06-21 |
2005-03-24 |
Pfizer Prod Inc |
Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels
|
US20050123509A1
(en)
*
|
2001-10-19 |
2005-06-09 |
Lehrman S. R. |
Modulating charge density to produce improvements in the characteristics of spray-dried proteins
|
US20050013867A1
(en)
*
|
2001-10-19 |
2005-01-20 |
Lehrman S. Russ |
Use of proton sequestering agents in drug formulations
|
CA2464656C
(en)
|
2001-11-01 |
2013-07-16 |
Nektar Therapeutics |
Spray drying methods and compositions thereof
|
ES2415654T3
(es)
*
|
2001-11-20 |
2013-07-26 |
Civitas Therapeutics, Inc. |
Composiciones particuladas mejoradas para suministro pulmonar
|
US20030099601A1
(en)
*
|
2001-11-27 |
2003-05-29 |
Gordon Marc S. |
Inhalation lung surfactant therapy
|
US20070203333A1
(en)
*
|
2001-11-30 |
2007-08-30 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050075304A1
(en)
*
|
2001-11-30 |
2005-04-07 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20040138163A1
(en)
*
|
2002-05-29 |
2004-07-15 |
Mcswiggen James |
RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
MXPA04005865A
(es)
|
2001-12-19 |
2004-09-13 |
Nektar Therapeutics |
Suministro de aminoglucosidos a los pulmones.
|
US20050042632A1
(en)
*
|
2002-02-13 |
2005-02-24 |
Sirna Therapeutics, Inc. |
Antibodies having specificity for nucleic acids
|
US20040014679A1
(en)
*
|
2002-02-20 |
2004-01-22 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20050137153A1
(en)
*
|
2002-02-20 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20040063912A1
(en)
*
|
2002-03-15 |
2004-04-01 |
The Brigham And Women's Hospital, Inc. |
Central airway administration for systemic delivery of therapeutics
|
EP1487992A4
(en)
*
|
2002-03-15 |
2007-10-31 |
Brigham & Womens Hospital |
CENTRAL AIRWAY DELIVERY FOR SYSTEMIC DRUG DELIVERY
|
US7008644B2
(en)
*
|
2002-03-20 |
2006-03-07 |
Advanced Inhalation Research, Inc. |
Method and apparatus for producing dry particles
|
AU2003218306B2
(en)
*
|
2002-03-20 |
2006-09-14 |
Advanced Inhalation Research, Inc. |
Method for administration of growth hormone via pulmonary delivery
|
EP1894591B1
(en)
|
2002-03-20 |
2013-06-26 |
MannKind Corporation |
Cartridge for an inhalation apparatus
|
US20050163725A1
(en)
*
|
2002-03-20 |
2005-07-28 |
Blizzard Charles D. |
Method for administration of growth hormone via pulmonary delivery
|
KR20050011741A
(ko)
|
2002-04-11 |
2005-01-29 |
메드이뮨 백신즈 인코포레이티드 |
분무 건조에 의한 생물학적 활성 물질의 보존
|
AU2003225182B2
(en)
*
|
2002-04-25 |
2009-02-26 |
Momenta Pharmaceuticals, Inc. |
Methods and products for mucosal delivery
|
GB0216562D0
(en)
*
|
2002-04-25 |
2002-08-28 |
Bradford Particle Design Ltd |
Particulate materials
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
DE10234165B4
(de)
*
|
2002-07-26 |
2008-01-03 |
Advanced Micro Devices, Inc., Sunnyvale |
Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
|
EP1581639A4
(en)
*
|
2002-12-17 |
2006-03-08 |
Medimmune Vaccines Inc |
HIGH PRESSURE PULVISATION OF BIOACTIVE MATERIALS
|
JP5591434B2
(ja)
|
2002-12-20 |
2014-09-17 |
ゼリス ファーマシューティカルズ インコーポレイテッド |
皮内注射方法
|
WO2004058218A2
(en)
*
|
2002-12-30 |
2004-07-15 |
Nektar Therapeutics |
Prefilming atomizer
|
KR20050095838A
(ko)
*
|
2002-12-31 |
2005-10-04 |
넥타르 테라퓨틱스 |
폐 투여용 불용성 활성제를 갖는 약제학적 제형물
|
MXPA05007156A
(es)
*
|
2002-12-31 |
2005-09-21 |
Nektar Therapeutics |
Formulacion farmaceuticas aerosolizable para terapia para infecciones fungicas.
|
KR100500675B1
(ko)
*
|
2003-02-10 |
2005-07-11 |
주식회사 에이앤피사이언스 |
고유량 입자 분무장치
|
GB0304540D0
(en)
*
|
2003-02-27 |
2003-04-02 |
Elan Drug Delivery Ltd |
Particle formulation and its preparation
|
KR20060015316A
(ko)
*
|
2003-05-28 |
2006-02-16 |
넥타르 테라퓨틱스 |
아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법
|
US20050014230A1
(en)
*
|
2003-07-16 |
2005-01-20 |
Ccl Holding Co., Ltd. |
Preparation of fully human antibodies
|
EA007368B1
(ru)
*
|
2003-07-28 |
2006-10-27 |
Пайонир Хай-Бред Интернэшнл, Инк. |
Устройство, способ и система для нанесения веществ на фураж, зерно или растительную массу перед или после уборки
|
US20050042180A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Powder formulation containing the CGRP antagonist 1 [N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2 (1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin, process for preparing and the use thereof as inhalation powder
|
US20050043247A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
|
US20050042179A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
|
US20050042178A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
|
GB0327723D0
(en)
*
|
2003-09-15 |
2003-12-31 |
Vectura Ltd |
Pharmaceutical compositions
|
WO2005032483A2
(en)
*
|
2003-10-01 |
2005-04-14 |
Momenta Pharmaceuticals, Inc. |
Polysaccharides for pulmonary delivery of active agents
|
US7338171B2
(en)
*
|
2003-10-27 |
2008-03-04 |
Jen-Chuen Hsieh |
Method and apparatus for visual drive control
|
US20050214224A1
(en)
*
|
2003-11-04 |
2005-09-29 |
Nektar Therapeutics |
Lipid formulations for spontaneous drug encapsulation
|
KR20050056799A
(ko)
*
|
2003-12-10 |
2005-06-16 |
엘지.필립스 엘시디 주식회사 |
액정 표시패널의 실 패턴 구조
|
EP1701714A2
(en)
|
2004-01-07 |
2006-09-20 |
Nektar Therapeutics |
Improved sustained release compositions for pulmonary administration of insulin
|
ES2584867T3
(es)
*
|
2004-01-12 |
2016-09-29 |
Mannkind Corporation |
Un método que reduce los niveles séricos de proinsulina en diabéticos de tipo 2
|
JP2007522246A
(ja)
*
|
2004-02-12 |
2007-08-09 |
ネクター セラピューティクス |
インターロイキン−13拮抗剤粉末剤、スプレードライ粒子、及び方法
|
ES2398318T3
(es)
*
|
2004-03-12 |
2013-03-15 |
Biodel, Inc. |
Composiciones de suministro de fármacos de acción rápida
|
US20080248999A1
(en)
*
|
2007-04-04 |
2008-10-09 |
Biodel Inc. |
Amylin formulations
|
US20080090753A1
(en)
|
2004-03-12 |
2008-04-17 |
Biodel, Inc. |
Rapid Acting Injectable Insulin Compositions
|
AU2005237523A1
(en)
|
2004-04-23 |
2005-11-10 |
Cydex Pharmaceuticals, Inc. |
DPI formulation containing sulfoalkyl ether cyclodextrin
|
US7727962B2
(en)
|
2004-05-10 |
2010-06-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Powder comprising new compositions of oligosaccharides and methods for their preparation
|
US7611709B2
(en)
|
2004-05-10 |
2009-11-03 |
Boehringer Ingelheim Pharma Gmbh And Co. Kg |
1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
|
US7723306B2
(en)
|
2004-05-10 |
2010-05-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
|
DE102004022926A1
(de)
*
|
2004-05-10 |
2005-12-15 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Sprühgetrocknete Pulver enthaltend zumindest ein 1,4 O-verknüpftes Saccharose-Derivat und Verfahren zu deren Herstellung
|
DE102004022928A1
(de)
*
|
2004-05-10 |
2005-12-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pulver enthaltend neuartige Oligosacharidgemische und Verfahren zu deren Herstellung
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
JP2008503586A
(ja)
*
|
2004-06-21 |
2008-02-07 |
ネクター セラピューティクス |
アンフォテリシンbを含む組成物、方法、およびシステム
|
US8513204B2
(en)
*
|
2004-06-21 |
2013-08-20 |
Novartis Ag |
Compositions comprising amphotericin B, mehods and systems
|
AU2005269753B2
(en)
|
2004-07-19 |
2011-08-18 |
Biocon Limited |
Insulin-oligomer conjugates, formulations and uses thereof
|
US20060024272A1
(en)
|
2004-07-29 |
2006-02-02 |
Large Scale Biology Corporation |
C-terminally truncated interferon
|
DK1786784T3
(da)
|
2004-08-20 |
2011-02-14 |
Mannkind Corp |
Katalyse af diketopiperazinsyntese
|
CN104436170B
(zh)
*
|
2004-08-23 |
2018-02-23 |
曼金德公司 |
用于药物输送的二酮哌嗪盐
|
SE0402345L
(sv)
*
|
2004-09-24 |
2006-03-25 |
Mederio Ag |
Uppmätt läkemedelsdos
|
US9149433B2
(en)
*
|
2004-11-30 |
2015-10-06 |
Basf Corporation |
Method for formation of micro-prilled polymers
|
US8968576B2
(en)
*
|
2004-11-30 |
2015-03-03 |
The Administrators Of The Tulane Educational Fund |
Nebulizing treatment method
|
WO2006076097A2
(en)
*
|
2004-12-07 |
2006-07-20 |
Nektar Therapeutics |
Stable non-crystalline formulation comprising losartan
|
WO2006078841A1
(en)
*
|
2005-01-21 |
2006-07-27 |
President And Fellows Of Harvard College |
Systems and methods for forming fluidic droplets encapsulated in particles such as colloidal particles
|
EP1866407A4
(en)
*
|
2005-03-22 |
2010-07-14 |
Regeron Inc |
DEVICE AND METHOD FOR SUBMICRONIZING PROTEINS USING SUPERCRITICAL LIQUIDS
|
BRPI0610062A2
(pt)
*
|
2005-05-18 |
2010-05-25 |
Nektar Therapeutics |
válvulas, dispositivos e métodos para terapia endobronquial
|
WO2007019554A2
(en)
*
|
2005-08-08 |
2007-02-15 |
Momenta Pharmaceuticals, Inc. |
Polysaccharides for delivery of active agents
|
HUE028623T2
(en)
|
2005-09-14 |
2016-12-28 |
Mannkind Corp |
Active substance formulation method based on increasing the affinity of the active ingredient for binding to the surface of crystalline microparticles
|
US20070086952A1
(en)
*
|
2005-09-29 |
2007-04-19 |
Biodel, Inc. |
Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
|
US8084420B2
(en)
*
|
2005-09-29 |
2011-12-27 |
Biodel Inc. |
Rapid acting and long acting insulin combination formulations
|
US7713929B2
(en)
|
2006-04-12 |
2010-05-11 |
Biodel Inc. |
Rapid acting and long acting insulin combination formulations
|
US7629331B2
(en)
|
2005-10-26 |
2009-12-08 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
US8293869B2
(en)
|
2005-12-16 |
2012-10-23 |
Nektar Therapeutics |
Polymer conjugates of GLP-1
|
US9012605B2
(en)
|
2006-01-23 |
2015-04-21 |
Amgen Inc. |
Crystalline polypeptides
|
BRPI0706947B8
(pt)
|
2006-01-24 |
2021-05-25 |
Ansun Biopharma Inc |
método de preparação de uma composição de micropartícula
|
GB0602897D0
(en)
*
|
2006-02-13 |
2006-03-22 |
Jagotec Ag |
Improvements In Or Relating To Dry Powder Inhaler Devices
|
IN2015DN00888A
(sh)
|
2006-02-22 |
2015-07-10 |
Mannkind Corp |
|
EP2012817A2
(en)
*
|
2006-04-12 |
2009-01-14 |
Biodel, Inc. |
Rapid acting and long acting insulin combination formulations
|
EP2080408B1
(en)
|
2006-10-23 |
2012-08-15 |
Starkey Laboratories, Inc. |
Entrainment avoidance with an auto regressive filter
|
GB0622818D0
(en)
*
|
2006-11-15 |
2006-12-27 |
Jagotec Ag |
Improvements in or relating to organic compounds
|
GB0625303D0
(en)
*
|
2006-12-19 |
2007-01-24 |
Jagotec Ag |
Improvements in and relating to metered dose inhalers
|
US7985058B2
(en)
*
|
2007-01-12 |
2011-07-26 |
Mark Gray |
Method and apparatus for making uniformly sized particles
|
EP2152304B1
(en)
*
|
2007-05-02 |
2018-08-22 |
The Regents of the University of Michigan |
Nanoemulsion therapeutic compositions and methods of using the same
|
WO2009045553A1
(en)
|
2007-10-05 |
2009-04-09 |
Barofold, Inc. |
High pressure treatment of aggregated interferons
|
AU2008340304B2
(en)
*
|
2007-12-21 |
2016-03-03 |
Aptevo Biotherapeutics Llc |
Stabilized factor IX formulations containing trehalose
|
EP2077132A1
(en)
|
2008-01-02 |
2009-07-08 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Dispensing device, storage device and method for dispensing a formulation
|
JP5352596B2
(ja)
*
|
2008-01-04 |
2013-11-27 |
バイオデル, インコーポレイテッド |
組織グルコースレベルの関数としてのインスリン放出のためのインスリン製剤
|
US8986253B2
(en)
|
2008-01-25 |
2015-03-24 |
Tandem Diabetes Care, Inc. |
Two chamber pumps and related methods
|
AU2009246217B2
(en)
|
2008-05-15 |
2013-01-10 |
Novartis Ag |
Pulmonary delivery of a fluoroquinolone
|
ES2570400T3
(es)
|
2008-06-13 |
2016-05-18 |
Mannkind Corp |
Un inhalador de polvo seco y un sistema para el suministro de fármacos
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
JP5479465B2
(ja)
|
2008-06-20 |
2014-04-23 |
マンカインド コーポレイション |
吸入努力をリアルタイムにプロファイルする対話式機器および方法
|
TWI532497B
(zh)
|
2008-08-11 |
2016-05-11 |
曼凱公司 |
超快起作用胰島素之用途
|
US8408421B2
(en)
|
2008-09-16 |
2013-04-02 |
Tandem Diabetes Care, Inc. |
Flow regulating stopcocks and related methods
|
EP2350118B1
(en)
|
2008-09-19 |
2016-03-30 |
Nektar Therapeutics |
Carbohydrate-based drug delivery polymers and conjugates thereof
|
EP2334234A4
(en)
|
2008-09-19 |
2013-03-20 |
Tandem Diabetes Care Inc |
DEVICE FOR MEASURING THE CONCENTRATION OF A SOLVED SUBSTANCE AND CORRESPONDING METHOD
|
JP5722782B2
(ja)
*
|
2008-09-26 |
2015-05-27 |
ナノバイオ コーポレーション |
ナノエマルジョン治療用組成物及びその使用方法
|
CN102239264B
(zh)
|
2008-10-03 |
2013-11-20 |
纳幕尔杜邦公司 |
含羧酸酯制剂中过水解酶的稳定
|
WO2010057197A1
(en)
|
2008-11-17 |
2010-05-20 |
The Regents Of The University Of Michigan |
Cancer vaccine compositions and methods of using the same
|
US9827205B2
(en)
*
|
2008-12-12 |
2017-11-28 |
Mallinckrodt Pharma Ip Trading D.A.C. |
Dry powder fibrin sealant
|
WO2010078373A1
(en)
|
2008-12-29 |
2010-07-08 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
US8314106B2
(en)
|
2008-12-29 |
2012-11-20 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
CA2753214C
(en)
|
2009-02-27 |
2017-07-25 |
Tandem Diabetes Care, Inc. |
Methods and devices for determination of flow reservoir volume
|
US9250106B2
(en)
|
2009-02-27 |
2016-02-02 |
Tandem Diabetes Care, Inc. |
Methods and devices for determination of flow reservoir volume
|
US9060927B2
(en)
*
|
2009-03-03 |
2015-06-23 |
Biodel Inc. |
Insulin formulations for rapid uptake
|
EP2405963B1
(en)
|
2009-03-11 |
2013-11-06 |
MannKind Corporation |
Apparatus, system and method for measuring resistance of an inhaler
|
JP2012520890A
(ja)
|
2009-03-18 |
2012-09-10 |
インカーダ セラピューティクス, インコーポレイテッド |
経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法
|
JP2012520684A
(ja)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いたBTBandCNCHomology1(塩基性ロイシンジッパー転写因子1)(Bach1)遺伝子発現のRNA干渉媒介性阻害
|
WO2010107958A1
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
JP2012520683A
(ja)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いた結合組織増殖因子(CTGF)遺伝子発現のRNA干渉媒介性阻害
|
EP2408915A2
(en)
|
2009-03-19 |
2012-01-25 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP2411516A1
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
CA2756069A1
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1)gene expression using short interfering nucleic acid (sina)
|
WO2010111471A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20120022143A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp |
RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
|
US20120004281A1
(en)
|
2009-03-27 |
2012-01-05 |
Merck Sharp & Dohme Corp |
RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
EP2414560B1
(de)
|
2009-03-31 |
2013-10-23 |
Boehringer Ingelheim International GmbH |
Verfahren zur beschichtung einer oberfläche eines bauteils
|
EP2413903A4
(en)
|
2009-04-01 |
2013-01-02 |
Promedior Inc |
PULMONARY AND NASAL ADMINISTRATION OF AMYLOID P SERUM SUBSTANCE
|
JP5763053B2
(ja)
|
2009-05-18 |
2015-08-12 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アダプタ、吸入器具及びアトマイザ
|
BRPI1012951A2
(pt)
|
2009-06-09 |
2016-07-26 |
Defyrus Inc |
"administração de interferon para profilaxia ou tratamento de infecção por patôgeno"
|
KR101875969B1
(ko)
|
2009-06-12 |
2018-07-06 |
맨카인드 코포레이션 |
한정된 비표면적을 갖는 디케토피페라진 마이크로입자
|
EP2932994B1
(en)
|
2009-07-30 |
2017-11-08 |
Tandem Diabetes Care, Inc. |
New o-ring seal, and delivery mechanism and portable infusion pump system related thereto
|
US8222012B2
(en)
|
2009-10-01 |
2012-07-17 |
E. I. Du Pont De Nemours And Company |
Perhydrolase for enzymatic peracid production
|
ES2679819T3
(es)
*
|
2009-11-03 |
2018-08-31 |
Grifols Therapeutics Inc. |
Composición, método y kit para inhibidor de alfa-1 proteinasa
|
JP5784622B2
(ja)
|
2009-11-03 |
2015-09-24 |
マンカインド コーポレ−ション |
吸入活動をシミュレートするための装置及び方法
|
JP5658268B2
(ja)
|
2009-11-25 |
2015-01-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ネブライザ
|
US10016568B2
(en)
|
2009-11-25 |
2018-07-10 |
Boehringer Ingelheim International Gmbh |
Nebulizer
|
WO2011064164A1
(en)
|
2009-11-25 |
2011-06-03 |
Boehringer Ingelheim International Gmbh |
Nebulizer
|
EP2330094B1
(en)
*
|
2009-12-03 |
2017-02-08 |
PURAC Biochem BV |
Alkali metal cinnamate powder and method for preparation
|
CN106701758B
(zh)
|
2009-12-09 |
2020-02-07 |
日东电工株式会社 |
Hsp47表达的调节
|
CN101816913B
(zh)
*
|
2010-05-20 |
2015-10-21 |
吴传斌 |
一种微球制造方法及制造设备
|
MX359281B
(es)
|
2010-06-21 |
2018-09-21 |
Mannkind Corp |
Sistema y metodos para suministrar un farmaco en polvo seco.
|
WO2011160932A1
(en)
|
2010-06-24 |
2011-12-29 |
Boehringer Ingelheim International Gmbh |
Nebulizer
|
US20120046225A1
(en)
|
2010-07-19 |
2012-02-23 |
The Regents Of The University Of Colorado, A Body Corporate |
Stable glucagon formulations for the treatment of hypoglycemia
|
EP3173079B1
(en)
|
2010-09-24 |
2020-04-22 |
University of Florida Research Foundation, Inc. |
Materials and methods for improving gastrointestinal function
|
ES2663009T3
(es)
|
2010-10-29 |
2018-04-10 |
Sirna Therapeutics, Inc. |
Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
|
EP2661254B1
(en)
|
2011-01-05 |
2017-08-02 |
Hospira, Inc. |
Spray drying vancomycin
|
ES2529429T3
(es)
*
|
2011-02-10 |
2015-02-20 |
Crucell Holland B.V. |
Sistema de separación de células de membrana de presión neumática alterna
|
US9808030B2
(en)
|
2011-02-11 |
2017-11-07 |
Grain Processing Corporation |
Salt composition
|
US8708159B2
(en)
*
|
2011-02-16 |
2014-04-29 |
Oakwood Laboratories, Llc |
Manufacture of microspheres using a hydrocyclone
|
WO2012114230A1
(en)
|
2011-02-25 |
2012-08-30 |
Koninklijke Philips Electronics N.V. |
An aerosol generating device for nebulizing a liquid and a method of temperature control of a liquid to be nebulized
|
CN103492572A
(zh)
|
2011-03-03 |
2014-01-01 |
夸克医药公司 |
用于治疗肺疾病和损伤的组合物和方法
|
EP3225235B1
(en)
|
2011-03-10 |
2020-12-16 |
Xeris Pharmaceuticals, Inc. |
Stable peptide formulations for parenteral injection
|
BR112013023062B1
(pt)
|
2011-03-10 |
2022-01-18 |
Xeris Pharmaceuticals, Inc |
Solução estável para a injeção parenteral e método de fabricação da mesma
|
WO2012130757A1
(de)
|
2011-04-01 |
2012-10-04 |
Boehringer Ingelheim International Gmbh |
Medizinisches gerät mit behälter
|
MX353285B
(es)
|
2011-04-01 |
2018-01-05 |
Mannkind Corp |
Paquete de blister para cartuchos farmaceuticos.
|
KR101763195B1
(ko)
*
|
2011-05-19 |
2017-07-31 |
사바라 인코포레이티드 |
건조 분말 반코마이신 조성물 및 관련 방법
|
US9572774B2
(en)
|
2011-05-19 |
2017-02-21 |
Savara Inc. |
Dry powder vancomycin compositions and associated methods
|
US9827384B2
(en)
|
2011-05-23 |
2017-11-28 |
Boehringer Ingelheim International Gmbh |
Nebulizer
|
US9011903B2
(en)
|
2011-06-08 |
2015-04-21 |
Nitto Denko Corporation |
Cationic lipids for therapeutic agent delivery formulations
|
TWI658830B
(zh)
|
2011-06-08 |
2019-05-11 |
日東電工股份有限公司 |
Hsp47表現調控強化用類視色素脂質體
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
ES2570184T3
(es)
|
2011-06-08 |
2016-05-17 |
Nitto Denko Corp |
Compuestos para dirigir la administración de fármacos y potenciar la actividad de ARNip
|
WO2012174472A1
(en)
|
2011-06-17 |
2012-12-20 |
Mannkind Corporation |
High capacity diketopiperazine microparticles
|
CN103945859A
(zh)
|
2011-10-24 |
2014-07-23 |
曼金德公司 |
用于治疗疼痛的方法和组合物
|
KR102196009B1
(ko)
|
2011-10-25 |
2021-01-04 |
프로테나 바이오사이언시즈 리미티드 |
항체 제형 및 방법
|
KR102007057B1
(ko)
|
2011-10-31 |
2019-08-02 |
엑스에리스 파머수티클스, 인크. |
당뇨병 치료를 위한 제형물
|
WO2013067281A1
(en)
*
|
2011-11-04 |
2013-05-10 |
Battelle Memorial Institute |
Processes for producing protein microparticles
|
EP2601941A1
(en)
|
2011-12-06 |
2013-06-12 |
Ludwig-Maximilians-Universität München |
Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
|
US9744318B2
(en)
|
2011-12-16 |
2017-08-29 |
Novartis Ag |
Aerosolization apparatus for inhalation profile-independent drug delivery
|
US9603906B2
(en)
|
2012-02-01 |
2017-03-28 |
Protalix Ltd. |
Inhalable liquid formulations of DNase I
|
EP2833891B1
(en)
|
2012-04-05 |
2018-07-25 |
University of Florida Research Foundation, Inc. |
Compostion for treatment of cystic fibrosis and for induction of ion secretion
|
US8753643B1
(en)
|
2012-04-11 |
2014-06-17 |
Life-Science Innovations, Llc |
Spray dried compositions and methods of use
|
WO2013152894A1
(de)
|
2012-04-13 |
2013-10-17 |
Boehringer Ingelheim International Gmbh |
Zerstäuber mit kodiermitteln
|
EP2836204B1
(en)
|
2012-04-13 |
2020-07-08 |
GlaxoSmithKline Intellectual Property Development Limited |
Aggregate particles
|
US9180242B2
(en)
|
2012-05-17 |
2015-11-10 |
Tandem Diabetes Care, Inc. |
Methods and devices for multiple fluid transfer
|
US9555186B2
(en)
|
2012-06-05 |
2017-01-31 |
Tandem Diabetes Care, Inc. |
Infusion pump system with disposable cartridge having pressure venting and pressure feedback
|
US9125805B2
(en)
|
2012-06-27 |
2015-09-08 |
Xeris Pharmaceuticals, Inc. |
Stable formulations for parenteral injection of small molecule drugs
|
US20140099380A1
(en)
|
2012-06-28 |
2014-04-10 |
Ansun Biopharma, Inc. |
Microparticle Formulations for Delivery to the Lower and Central Respiratory Tract and Methods of Manufacture
|
WO2014012069A2
(en)
|
2012-07-12 |
2014-01-16 |
Mannkind Corporation |
Dry powder drug delivery systems and methods
|
EP2911690A1
(en)
|
2012-10-26 |
2015-09-02 |
MannKind Corporation |
Inhalable influenza vaccine compositions and methods
|
US9757395B2
(en)
|
2012-12-20 |
2017-09-12 |
Otitopic Inc. |
Dry powder inhaler and methods of use
|
US9757529B2
(en)
|
2012-12-20 |
2017-09-12 |
Otitopic Inc. |
Dry powder inhaler and methods of use
|
US9018162B2
(en)
|
2013-02-06 |
2015-04-28 |
Xeris Pharmaceuticals, Inc. |
Methods for rapidly treating severe hypoglycemia
|
US9956287B2
(en)
|
2013-02-06 |
2018-05-01 |
Perosphere Inc. |
Stable glucagon formulations
|
WO2014164736A1
(en)
|
2013-03-11 |
2014-10-09 |
University Of Florida Research Foundation, Incorporated |
Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications
|
US9173998B2
(en)
|
2013-03-14 |
2015-11-03 |
Tandem Diabetes Care, Inc. |
System and method for detecting occlusions in an infusion pump
|
CN104043104B
(zh)
|
2013-03-15 |
2018-07-10 |
浙江创新生物有限公司 |
含盐酸万古霉素的喷雾干粉及其工业化制备方法
|
AU2014228415B2
(en)
|
2013-03-15 |
2018-08-09 |
Mannkind Corporation |
Microcrystalline diketopiperazine compositions and methods
|
EP3607941A1
(en)
|
2013-04-30 |
2020-02-12 |
Otitopic Inc. |
Dry powder formulations and methods of use
|
WO2014207213A1
(en)
|
2013-06-28 |
2014-12-31 |
Medizinische Universität Innsbruck |
Novel inhibitors of protein kinase c epsilon signaling
|
KR102321339B1
(ko)
|
2013-07-18 |
2021-11-02 |
맨카인드 코포레이션 |
열-안정성 건조 분말 약제학적 조성물 및 방법
|
US11446127B2
(en)
|
2013-08-05 |
2022-09-20 |
Mannkind Corporation |
Insufflation apparatus and methods
|
JP6643231B2
(ja)
|
2013-08-09 |
2020-02-12 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ネブライザ
|
EP2835146B1
(en)
|
2013-08-09 |
2020-09-30 |
Boehringer Ingelheim International GmbH |
Nebulizer
|
ES2922206T3
(es)
|
2014-02-20 |
2022-09-09 |
Otitopic Inc |
Formulaciones de polvo seco para la inhalación
|
US10307464B2
(en)
|
2014-03-28 |
2019-06-04 |
Mannkind Corporation |
Use of ultrarapid acting insulin
|
PL3139984T3
(pl)
|
2014-05-07 |
2021-11-08 |
Boehringer Ingelheim International Gmbh |
Nebulizator
|
JP6580070B2
(ja)
|
2014-05-07 |
2019-09-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
容器、ネブライザ、及び使用
|
LT3928818T
(lt)
|
2014-05-07 |
2023-03-27 |
Boehringer Ingelheim International Gmbh |
Purkštuvas ir talpa
|
EP2947460A1
(en)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
|
CA2954287C
(en)
|
2014-07-08 |
2020-12-22 |
Amphastar Pharmaceuticals, Inc. |
Methods of preparing inhalable micronized insulin for pulmonary delivery
|
AU2015300944B2
(en)
|
2014-08-06 |
2019-07-11 |
Xeris Pharmaceuticals, Inc. |
Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
|
US10575417B2
(en)
|
2014-09-08 |
2020-02-25 |
The Stanley Works Israel Ltd. |
Jobsite communications center
|
US10561806B2
(en)
|
2014-10-02 |
2020-02-18 |
Mannkind Corporation |
Mouthpiece cover for an inhaler
|
US20170304459A1
(en)
|
2014-10-10 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
EP4112076A1
(en)
|
2014-10-10 |
2023-01-04 |
The Regents of The University of Michigan |
Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
|
EP3212212B1
(en)
|
2014-10-31 |
2020-09-23 |
Monash University |
Powder formulation
|
EP3459540A1
(en)
|
2014-11-24 |
2019-03-27 |
Entrinsic Health Solutions, Inc. |
Amino acid compositions for the treatment of symptoms of disease
|
CA2970216A1
(en)
|
2015-01-04 |
2016-07-07 |
Protalix Ltd. |
Modified dnase and uses thereof
|
WO2016135138A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135139A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135140A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135137A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016170102A1
(en)
|
2015-04-22 |
2016-10-27 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
CN108744187A
(zh)
*
|
2015-05-16 |
2018-11-06 |
苏州汉方医药有限公司 |
由手动悬浮微颗粒发生器和刺五加或刺五加总皂组成的药盒
|
WO2016196976A1
(en)
|
2015-06-04 |
2016-12-08 |
Xeris Pharmaceuticals, Inc. |
Glucagon delivery apparatuses and related methods
|
US9649364B2
(en)
|
2015-09-25 |
2017-05-16 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic formulations in aprotic polar solvents
|
WO2016201248A1
(en)
|
2015-06-10 |
2016-12-15 |
Xeris Pharmaceuticals, Inc. |
Use of low dose glucagon
|
US11590205B2
(en)
|
2015-09-25 |
2023-02-28 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
|
ES2898704T3
(es)
|
2015-12-09 |
2022-03-08 |
Univ Wien Med |
Compuestos de platino funcionalizados con monomaleimida para la terapia del cáncer
|
CN106968984B
(zh)
*
|
2015-12-11 |
2020-10-23 |
松下知识产权经营株式会社 |
涡轮机
|
US10322168B2
(en)
|
2016-01-07 |
2019-06-18 |
Amphastar Pharmaceuticals, Inc. |
High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
|
EP3402788A1
(en)
|
2016-01-15 |
2018-11-21 |
Universität Hamburg |
Flavonoide-type compounds bearing an o-rhamnosyl residue
|
US11833118B2
(en)
|
2016-01-20 |
2023-12-05 |
Flurry Powders, Llc |
Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
|
WO2017127641A1
(en)
|
2016-01-20 |
2017-07-27 |
Flurry Powders |
Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
|
IL260335B2
(en)
|
2016-02-01 |
2023-10-01 |
Incarda Therapeutics Inc |
Combining electronic monitoring with inhaled pharmacological therapy for the management of cardiac arrhythmia including atrial fibrillation
|
MX2018009870A
(es)
|
2016-02-15 |
2018-11-29 |
Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh |
Inhibidores de taf1 para la terapia del cancer.
|
PL3280414T3
(pl)
|
2016-04-15 |
2024-06-24 |
Oxford University Innovation Limited |
Modulatory receptora adenozyny w leczeniu schorzeń rytmu okołodobowego
|
US10704425B2
(en)
*
|
2016-07-14 |
2020-07-07 |
General Electric Company |
Assembly for a gas turbine engine
|
EP3522882A4
(en)
|
2016-10-04 |
2020-06-24 |
The University of Florida Research Foundation Incorporated |
AMINO ACID COMPOSITIONS AND USES THEREOF
|
JP2020511401A
(ja)
|
2016-11-14 |
2020-04-16 |
チェム−フォルシュングスツェントルン フュル モレクラーレ メディツィン ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌の治療法のためのbrd4阻害剤と葉酸代謝拮抗薬との組み合わせ物
|
AU2018266199A1
(en)
|
2017-05-10 |
2019-11-07 |
Incarda Therapeutics, Inc. |
Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
|
WO2018217800A1
(en)
|
2017-05-22 |
2018-11-29 |
Insmed Incorporated |
Glycopeptide derivative compounds and uses thereof
|
CN110709061B
(zh)
|
2017-06-02 |
2023-09-08 |
Xeris药物公司 |
抗沉淀的小分子药物制剂
|
US10391154B2
(en)
|
2017-07-19 |
2019-08-27 |
Leadiant Biosciences Ltd. |
Compositions and methods for treating or ameliorating fibrosis, systemic sclerosis and scleroderma
|
EP3720850A1
(en)
|
2017-12-05 |
2020-10-14 |
ETH Zurich |
New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
|
EP3768378A4
(en)
|
2018-03-22 |
2021-11-17 |
InCarda Therapeutics, Inc. |
INNOVATIVE METHOD OF SLOWING THE VENTRICULAR RATE
|
WO2019193161A1
(en)
|
2018-04-06 |
2019-10-10 |
Universität Wien |
Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs
|
EA202092326A1
(ru)
|
2018-04-06 |
2021-03-19 |
Цилентин Аг |
Производные буметанида для лечения гипергидроза
|
ES2949701T3
(es)
|
2018-07-26 |
2023-10-02 |
Cvie Therapeutics Ltd |
Compuestos similares al 17beta-heterociclil-digitalis para el tratamiento de la insuficiencia cardíaca
|
US20230067929A1
(en)
|
2018-12-17 |
2023-03-02 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
|
BR112021021775A2
(pt)
|
2019-04-29 |
2022-01-04 |
Insmed Inc |
Composições de pó seco de pró-fármacos de treprostinil e métodos de uso destas
|
RU193395U1
(ru)
*
|
2019-06-17 |
2019-10-28 |
Евгений Викторович Крейдин |
Генератор сухого солевого аэрозоля
|
US11007185B2
(en)
|
2019-08-01 |
2021-05-18 |
Incarda Therapeutics, Inc. |
Antiarrhythmic formulation
|
US20230064948A1
(en)
|
2019-10-02 |
2023-03-02 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
WO2021064141A1
(en)
|
2019-10-02 |
2021-04-08 |
Tolremo Therapeutics Ag |
Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
|
EP3805243B1
(en)
|
2019-10-09 |
2023-11-15 |
Windtree Therapeutics, Inc. |
Androstane derivatives with activity as pure or predominantly pure stimulators of serca2a for the treatment of heart failure
|
WO2021074418A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
IL292153A
(en)
|
2019-10-16 |
2022-06-01 |
Cemm Forschungszentrum Fur Molekulare Medizin Gmbh |
Oxazole and thiazole choline ubiquitin ligase ring compounds and uses thereof
|
EP4138884A1
(en)
|
2020-04-20 |
2023-03-01 |
Sorrento Therapeutics, Inc. |
Pulmonary administration of ace2 polypeptides
|
WO2021260110A1
(en)
|
2020-06-25 |
2021-12-30 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
|
CA3184282A1
(en)
|
2020-06-27 |
2021-12-30 |
Emre Koyuncu |
Composition of compounds that modulate cell metabolism and methods of use
|
EP3939578A1
(en)
|
2020-07-13 |
2022-01-19 |
Novaremed Ltd. |
Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
|
EP3964497A1
(en)
|
2020-09-04 |
2022-03-09 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
|
WO2022074656A1
(en)
|
2020-10-07 |
2022-04-14 |
Protalix Ltd. |
Long-acting dnase
|
AU2021359129A1
(en)
|
2020-10-16 |
2023-06-01 |
Proxygen Gmbh |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
TW202304882A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商妥瑞莫醫療公司 |
雜環衍生物、醫藥組成物及彼等於治療或改善癌症之用途
|
WO2023150747A1
(en)
|
2022-02-07 |
2023-08-10 |
Insmed Incorporated |
Dry powder compositions of bedaquiline and salts and methods of use thereof
|
WO2023203172A1
(en)
|
2022-04-20 |
2023-10-26 |
Proxygen Gmbh |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|